Is it Time to Dump Compass Therapeutics Inc. (CMPX) Stock After it Has Risen 11.55% in a Week?

Overall market sentiment has been high on Compass Therapeutics Inc. (CMPX) stock lately. CMPX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Compass Therapeutics Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CMPX!

See Full CMPX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CMPX Stock Today?

Compass Therapeutics Inc. (CMPX) stock is trading at $2.80 as of 12:20 PM on Monday, Jul 31, an increase of $0.13, or 4.82% from the previous closing price of $2.67. The stock has traded between $2.80 and $3.01 so far today. Volume today is low. So far 329,678 shares have traded compared to average volume of 911,800 shares.

More About Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. The company has drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases. Click Here to get the full Stock Report for Compass Therapeutics Inc. stock.